[Effects of pepleomycin (PEP) infused through bronchial artery for lung cancer: in comparison with the cases of mitomycin (MMC) or carboquon (CQ)].
(1) Therapeutic effects of bronchial artery infusion (BAI) of peplomycin (PEP), a derivative of bleomycin, were examined in the 13 patients with lung cancer. The effectiveness of PEP was compared with that of 59 patients treated with mitomycin (MMC) or carboquon (CQ). (2) In all cases treated with PEP, histopathological effects revealed to be more than grade IIa of Shimosato's criteria, which were more effective than that with MMC or CQ. (3) Histopathological changes of the metastatic lymph nodes were similar to that of the main tumor. (4) In the cases treated with PEP, tumor decreased rates shown in the chest X-ray films 2 weeks after BAI were lower than that with MMC or CQ. Cavity formation in the tumor was recognized in 62% of the cases treated with PEP. (5) Low fever lasting several days after administration of BAI and GI symptoms such as nausea and vomiting were main side effects, which were mild and not so serious.
D000230:Adenocarcinoma / Q000188:drug therapy; D001389:Azirines / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D001981:Bronchial Arteries; D002225:Carbazilquinone / Q000008:administration & dosage*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000188:drug therapy*; D008937:Mitomycins / Q000008:administration & dosage*; D017663:Peplomycin
D001389:Azirines; D008937:Mitomycins; D001761:Bleomycin; D002225:Carbazilquinone; D017663:Peplomycin